兰瑞肽,CAS 登记号 118992-92-0,由济南圣和化工有限公司现货供应,可提供纯度 按批次COA提供(不公开发布) 的规格,下游主要用于有机化学品。支持样品与小批量试用,批量价格请联系我们获取,验收以批次 COA 为准。
有机化学品
每批随货提供 COA;可按需提供 MSDS 及技术文件。邮件注明产品名称与 CAS 号,一个工作日内回复报价。
本页已列出 兰瑞肽 的 CAS 号:118992-92-0,可与随货 COA 核对。
常见纯度为 按批次COA提供(不公开发布),包装形式为 按订单/批次确认(不公开发布),特殊规格可在询价时说明。
主要涉及有机化学品。
来信 info@591daili.com 或 WhatsApp 联系,提供产品名称、CAS 号与数量,确认价格与交期后即可安排发货,验收以批次 COA 为准。
lanreotide · CAS 118992-92-0 · C54H69N11O10S2. UNII 0G3DE8943Y.
| CAS Registry Number | 118992-92-0 |
|---|---|
| PubChem CID | 6918011 |
| Molecular formula | C54H69N11O10S2 |
| IUPAC name | (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide |
| UNII (FDA) | 0G3DE8943Y |
| Molecular Weight | 1096.3 |
|---|---|
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 13 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 17 |
| Exact Mass | 1095.46702979 |
| Monoisotopic Mass | 1095.46702979 |
| Topological Polar Surface Area | 406 |
| Heavy Atom Count | 77 |
| Formal Charge | 0 |
| Reported hazard statements | H361 (100%) |
|---|
H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Lanreotide; 108736-35-2; Ipstyl; Lanreotida; Lanreotidum; Lanreotide Autogel; BIM 23014; Bim-23014; DC 13-116; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; DTXSID60897514; 0G3DE8943Y; Somatulina; Somatuline LA; BIM 23014C; DC13-116
CAS 118992-92-0; molecular formula C54H69N11O10S2; molecular weight — g/mol.
Lanreotide, 108736-35-2, Ipstyl, Lanreotida, Lanreotidum, Lanreotide Autogel.
Hazard statements reported: H361.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.